Dr Reddy's Laboratories launches generic anti-cancer drug in US market

Gleevec and its generic equivalents saw sales of approximately $868 mn in the US for the last twelve months ending in July 2018

Dr Reddy's Laboratories Limited on Monday announced the launch of Imatinib Mesylate tablets, a generic version of Novartis' blockbuster anti-cancer drug Gleevec, in the US market.

The drug is used in treating chronic myeloid leukaemia.

The company has received US Food and Drug Administration (USFDA) approval to manufacture and market the product. 

Gleevec and its generic equivalents saw sales of approximately $868 million in the US for the last twelve months ending in July 2018, the company said quoting the IMS Health statistics. In a recent report, IIFL said it was forecasting $34 million of revenues from the sale of